Clinical Trial Update: Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC [Phase 1]

View source ↗

Summary

Phase 1 trial of Mirvetuximab Soravtansine (IMG853) in folate receptor alpha-expressing triple-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Mirvetuximab soravtansine (mirvetuximab soravtansine)

Snippet

Sponsor: Duke University | Conditions: Breast Cancer Triple Negative | Phase 1 | Status: WITHDRAWN